Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of March 30, 2026 [3]. Core Insights - The innovative drug sector is experiencing a significant configuration opportunity, with major domestic pharmaceutical companies reporting rapid growth in innovative drugs. The development model has shifted from solely relying on financing to a comprehensive approach that includes product commercialization, overseas R&D licensing, and financing [4]. - The Chinese innovative drug market has seen a surge in business development (BD) events, with 49 BD events recorded in 2026, totaling over $33 billion in upfront payments and nearly $570 billion in total deal value. The first quarter of 2026 alone surpassed the total transaction volume of 2024 [4]. - The innovative drug index outperformed the CSI 300 index by 4.44 percentage points during the week of March 21-27, 2026, with a growth rate of 3.03% [4]. Summary by Sections 1. Innovative Drug Highlights - Major domestic pharmaceutical companies like Heng Rui Medicine and China Biopharmaceuticals have reported rapid growth in innovative drugs, with biotech firms like BeiGene and Innovent Biologics turning significant losses into profits [4]. - The trend of Chinese innovative drugs going global is strong, with a notable increase in BD events and a focus on clinical data quality and long-term market value [4]. 2. Tumor Immunotherapy 2.0 Era - China continues to lead in the development of PD-1/VEGF bispecific antibodies, with significant partnerships and clinical advancements. The market potential for PD-1 bispecifics is expected to surpass that of PD-1 monotherapy [5]. - The collaboration between domestic companies and multinational corporations (MNCs) is intensifying, with a focus on clinical data and market rights sharing [5]. 3. New Technologies and Molecules - The ADC (Antibody-Drug Conjugate) sector is witnessing innovation, with new technologies being integrated to overcome limitations of existing ADCs. The introduction of various therapeutic modalities is expected to expand the applicability of ADCs [6]. 4. Small RNA Collaborations - The small RNA sector is seeing increased mergers and collaborations, with significant deals being made to develop innovative therapies for metabolic disorders. The market for small RNA drugs is rapidly industrializing, with notable sales growth for products like Leqvio [7]. 5. Price Control and Raw Materials - The report highlights the price elasticity of certain raw materials, particularly vitamins, which have seen significant price increases due to geopolitical factors and supply chain dynamics. Vitamin E and A prices have risen by 81.98% and 76% respectively since the beginning of the year [9]. 6. CDMO and CXO Trends - The report emphasizes the importance of CDMO (Contract Development and Manufacturing Organization) in driving orders for large products, with recommendations for companies like Yino Science and Pruis [12]. 7. Recommended Companies and Stock Picks - The report suggests focusing on companies leading in innovative drugs, ADC technology, small RNA therapies, and those with pricing power in raw materials. Specific recommendations include Rongchang Biopharmaceuticals, Sunway Biopharma, and others [12][13].

Core Viewpoint - 康方生物 is positioned to lead the next generation of tumor immunotherapy with its innovative dual-antibody platform and strong pipeline of products [1][2][3] Group 1: Company Overview - 康方生物 focuses on developing innovative antibody drugs, utilizing its ACE platform and Tetrabody technology to support over 20 pipelines [1] - The company achieved a significant milestone with the approval of AK104, the world's first PD-1/CTLA-4 dual antibody, in 2022 [1] - 康方生物 has a robust cash position of 7.3 billion RMB in 2024, which supports the commercialization of its pipeline [1] Group 2: Product Pipeline and Market Potential - AK112 has outperformed K drug in head-to-head trials and is expected to become a cornerstone product in the global immuno-oncology market, with peak revenue projections of 17.1 billion RMB by 2035 [2] - AK104 is the only approved PD-1/CTLA-4 dual antibody, with ongoing clinical trials expanding its indications, including cervical and gastric cancers [3] - The company anticipates rapid revenue growth from AK104 and AK112, with projected revenues of 3.67 billion, 5.34 billion, and 7.24 billion RMB for 2025-2027 [4] Group 3: Financial Projections and Valuation - The valuation of 康方生物 is projected at 160 billion HKD based on the potential of AK104 and AK112, with domestic revenue estimated at 3x PS and overseas at 15x PE [4] - The FCFF model indicates a target price of 163.33 RMB, suggesting significant upside potential compared to the closing price on July 7, 2025 [4]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company is positioned as a leader in the dual antibody sector, spearheading a new era in immuno-oncology with its innovative products, particularly AK104 and AK112, which are nearing commercialization [8][13]. - The revenue forecast indicates significant growth, with projected revenues of 3.672 billion, 5.342 billion, and 7.240 billion CNY for 2025, 2026, and 2027 respectively, reflecting a strong upward trajectory [1][24]. - The company has a robust cash reserve of 7.344 billion CNY, which supports ongoing research and development efforts [29]. Summary by Sections Company Overview - The company focuses on developing innovative antibody drugs and has established a comprehensive drug development platform, ACE, with over 20 product pipelines [13][14]. - It has successfully launched the world's first dual immune checkpoint inhibitor, AK104, for cervical cancer in June 2022, and is expanding its product offerings [13][14]. Financial Performance - The company reported total revenue of 2.124 billion CNY in 2024, with a significant increase in product sales revenue to approximately 2.002 billion CNY, marking a year-on-year growth of 24.88% [24][25]. - The gross profit margin remains high at 86.39%, indicating strong profitability relative to industry standards [25][28]. Product Pipeline - AK104 is the only approved PD-1/CTLA-4 dual antibody globally, with multiple indications approved and ongoing clinical trials for additional cancers [33][34]. - AK112 is also positioned to challenge existing therapies, with promising clinical trial results and a strong market potential [8][19]. Market Position and Future Outlook - The company is expected to achieve a market valuation of 160 billion HKD based on the anticipated revenues from its core products [8]. - The report projects a target price of 163.33 CNY per share, indicating a potential upside from the current market price [8].